The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...